Brent Rexer
Faculty Member
Last active: 2/13/2015


None provided


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Outsmarting cancer: the power of hybrid genomic/proteomic biomarkers to predict drug response. Rexer BN, Arteaga CL (2014) Breast Cancer Res 16(2): 303
    › Primary publication · 25032256 (PubMed) · PMC4053204 (PubMed Central)
  2. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Rexer BN, Chanthaphaychith S, Dahlman K, Arteaga CL (2014) Breast Cancer Res 16(1): R9
    › Primary publication · 24451154 (PubMed) · PMC3978602 (PubMed Central)
  3. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, Engelman JA, Arteaga CL (2013) Clin Cancer Res 19(19): 5390-401
    › Primary publication · 23948973 (PubMed) · PMC3809918 (PubMed Central)
  4. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Rexer BN, Ham AJ, Rinehart C, Hill S, Granja-Ingram Nde M, González-Angulo AM, Mills GB, Dave B, Chang JC, Liebler DC, Arteaga CL (2011) Oncogene 30(40): 4163-74
    › Primary publication · 21499296 (PubMed) · PMC3204390 (PubMed Central)
  5. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga CL (2010) Oncogene 29(37): 5193-203
    › Primary publication · 20581867 (PubMed) · PMC2945381 (PubMed Central)